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Abstract
Background: Active smoking increases asthma severity and is related to diminished treatment
efficacy. Animal models in which inhalation of both allergen and mainstream cigarette smoke are
combined can help us to understand the complex interaction between both agents. We have
recently shown that, in allergic mice, the airway inflammation can be cleared by repeated allergen
challenge, resulting in the establishment of a state of inhalational tolerance.
Methods: In this study, we assessed in vivo the impact of cigarette smoke on the efficacy and time
course of this form of tolerance induction. We exposed sensitized mice to concurrent mainstream
cigarette smoke and allergen (Ovalbumin- OVA) and measured the airway inflammation at different
time points.
Results: We first confirmed that aerosolized OVA administered for a prolonged time period (4–
8 weeks) resulted in the establishment of tolerance. Concurrent OVA and smoke exposure for 2
weeks showed that tobacco smoke enhanced the Th-2 driven airway inflammation in the acute
phase. In addition, the induction of the tolerance by repeated inhalational OVA challenge was
delayed significantly by the tobacco smoke, since 4 weeks of concurrent exposure resulted in a
more persistent eosinophilic airway inflammation, paralleled by a more mature dendritic cell
phenotype. However, smoke exposure could not prevent the establishment of tolerance after 8
weeks of antigen exposure as shown by both histopathology (disappearance of the Th-2 driven
inflammation) and by in vivo functional experiments. In these tolerized mice, some of the
inflammatory responses to the smoke were even attenuated.
Conclusion: Cigarette smoke enhances acute allergic inflammation and delays, but does not
abrogate the development of tolerance due to prolonged challenge with inhaled antigen in
experimental asthma.
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Background
Immune-mediated tolerance encompasses a number of
mechanisms by which the immune system avoids unnec-
essary inflammatory responses, not only in face of auto-
allergens but also to harmless environmental antigens [1].
It has been suggested that the beneficial and often long-
lasting effects of allergen specific immunotherapy in
patients with allergy are due to a stimulation of these
immune-suppressive mechanisms [2]. We and others
have found that prolonged exposure to aerosolized aller-
gen in sensitized mice is accompanied with a disappear-
ance of the eosinophilic airway inflammation [3-6] under
certain conditions of antigenic stimulation, resulting in a
state of inhalational tolerance [3,6]. Although a more per-
sistent inflammation in experimental models of asthma
can be obtained [7-10], the observation that the inflam-
mation disappears under particular conditions of anti-
genic stimulation remains of potential importance, as it
indicates that the vertebrate immune system has an inher-
ent capacity to avoid unnecessary immunity and to restore
homeostasis after an episode of allergen-induced airway
inflammation. Studying the mechanisms involved in this
phenomenon can provide us valuable new insights in the
mechanisms regulating immune responses in the respira-
tory tract.
As a state of inhalational tolerance can be re-established in
vivo  [3,6], the question arises of its susceptibility and
robustness in face of the numerous environmental factors
that are known to aggravate the allergic condition [11,12].
One of the most important of such factors is mainstream
cigarette smoke. To date, little is known about the effects
of smoking on the efficacy of immunotherapy treatments
in patients. Nevertheless, from animal models, we know
that mainstream cigarette smoke has the potential to
break primary inhalational tolerance to allergens in naïve
animals [13] and to increase the systemic sensitization to
surrogate and environmental allergens [14]. Several other
studies have documented similar properties of second
hand smoke or environmental tobacco smoke [15,16].
More conflicting data were reported on the effects of
mainstream cigarette smoke in an ongoing acute Th-2
driven inflammatory response. While concurrent expo-
sure to allergen and cigarette smoke was shown to aggra-
vate allergic airway inflammation [17], tobacco smoke
exposure following an initial period of allergen challenge,
attenuated airway hyperresponsiveness and airway
inflammation [14,18].
We hypothesized that mainstream cigarette smoke expo-
sure could interfere with the induction of inhalational tol-
erance, thereby inducing a more persistent eosinophil-
rich airway inflammation. This basic hypothesis seemed
plausible from a theoretical point of view, since active
smoking is associated with asthma exacerbations and
reduced efficacy of treatment in humans [19] and main-
stream cigarette smoke was able to break primary inhala-
tional tolerance in naïve mice [13]. Active smoking could
thus serve as an environmental factor that helps to explain
why in patients with allergic asthma, the failure of
immune tolerance persists. Therefore, we here analysed
the effects of cigarette smoke exposure on the efficacy of
inhalational tolerance induction in allergic mice.
Methods
Animals
Male C57BL/6 mice, 6 to 8 weeks old, were purchased
from Harlan (Zeist, the Netherlands). All experimental
procedures were approved by the local ethical committee
for animal experiments (Faculty of Medicine and Health
Sciences, Ghent University).
Experimental Protocols
Allergen Protocol 1
OVA aerosol exposure
1.1. Allergen Protocol 1A
Allergic airway inflammation
Two groups of 8 mice were sensitized with 10 µg intraperi-
toneal (i. p.) OVA (Grade III; Sigma, St-Louis, MO)
adsorbed to 1 mg Al(OH)3 on day 0 (d0) and d7. From
d14 onward, the mice were exposed to aerosolized (Ultra-
schallvernebler Sirius Nova, Heyer Medizintechnologie,
Bad Ems, Germany) OVA (1% wt/v) or PBS 30 min/d, 3
times a week for 2 weeks (Figure 1 – Allergen Protocol 1A).
1.2. Allergen Protocol 1B
Tolerance
Two groups of mice (n = 8/group) were sensitized with i.
p. OVA/alum on day 0 (d0) and d7. From d14 onward,
the mice were subjected to prolonged OVA or PBS aerosol
exposures for 8 weeks (Figure 1 – Allergen Protocol 1B).
Smoke Protocol
Mainstream cigarette smoke exposure in vivo
To show that exposure to mainstream cigarette smoke for
8 weeks is biologically active in C57BL/6 mice, two groups
of 6 mice were exposed to either Smoke or Air for 8 weeks.
Tobacco smoke exposures were performed in a plexiglass
chamber (volume: 7500 cm3) with an inlet for pressured
air (2.5 l/min). The chamber was connected to a smoking
machine (D. Kobayashi, Washington University Medical
Center, WA, USA). Exposures were performed four times
a day, 5 days a week, with five Kentucky Reference ciga-
rettes (2R4F, without filter) for six mice per exposure (Fig-
ure 1 – Smoke Protocol). The effects of this smoking
protocol in mice at various other time points have beenRespiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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Cigarette smoke and allergen exposure protocols Figure 1
Cigarette smoke and allergen exposure protocols. Allergen exposure protocols (Allergen Protocols): Allergen Pro-
tocol 1A: Exposure of sensitized C57BL/6 mice to PBS or OVA aerosols for 2 weeks. (n = 8 mice/group). Allergen Protocol 1B: 
Prolonged PBS or OVA aerosol exposure in sensitized mice (8 weeks). (n = 8 mice/group). Allergen Protocol 2: OVA sensitized 
mice were exposed to OVA for 8 weeks ("chronic"), followed by HEL/alum immunisation and short-term ("acute") HEL aero-
sol challenge (OVA/HEL group). Control mice were exposed to PBS for 8 weeks, immunized with HEL/alum and challenged 
with either PBS (PBS/PBS group) or with HEL (PBS/HEL group). (n = 8–12 mice/group). Smoke exposure protocol (Smoke 
Protocol): C57BL/6 mice are exposed to Smoke or Air for 8 weeks. (n = 6 mice/group). Combined protocols (Combina-
tion Protocols): Combination Protocol 1: similar to Allergen Protocol 1B, combined with Smoke exposures or Air. (n = 8 mice/
group). Combination Protocol 2: similar to Allergen Protocol 2, combined with or without Smoke. (n = 8 mice/group). Combination 
Protocol 3A: similar to Allergen Protocol 1A, combined with Smoke exposures or Air. (n = 8 mice/group). Combination Protocol 3B: 
4 weeks of OVA aerosol or PBS exposures in sensitized mice, combined with Smoke exposures or Air. (n = 8 mice/group). 
Vertical arrows = aerosol challenges (OVA, HEL or PBS). Stripped horizontal bars = period of Smoke or Air exposures.Respiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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carefully characterized in earlier experiments by our labo-
ratory[20]. Carboxyhemoglobin in the serum of mice
exposed to this smoke protocol reached a non-toxic level
of 8.3 ± 1.4% (compared with 1.0 ± 0.2% in air-exposed
mice), which is similar to COHb blood concentrations of
human smokers.
Combination Protocol 1
Smoke combined with long – term OVA aerosol exposure.
To evaluate the effect of cigarette smoke on the develop-
ment of tolerance, four groups of mice (n = 8/group) were
subjected to this tolerance induction protocol (OVA or
PBS aerosols), combined with Smoke or Air. Smoke expo-
sures were performed as described above in the Smoke pro-
tocol, with eight mice per exposure. Three times a week,
smoke exposure was followed by OVA or PBS aerosols.
The last smoke exposure took place 30 min before OVA or
PBS aerosol. (Figure 1 – Combination Protocol 1).
Allergen Protocol 2
OVA and HEL aerosol exposures
To measure the immune responsiveness after chronic
OVA exposure, OVA sensitized mice (n = 8–12/group),
subjected to the tolerance protocol (8 wk OVA aerosols),
were re-sensitized to a bystander allergen, Hen Egg Lys-
ozyme (HEL, Sigma, St-Louis, MO; 10 µg HEL/alum i.p.)
and re-challenged with daily HEL (1%) for 1 week ('OVA/
HEL' group). OVA sensitized, PBS aerosol exposed mice
were also re-immunized and challenged with HEL and
were included as positive controls ('PBS/HEL' group). A
negative control group ('PBS/PBS') was included as well
(Figure 1 – Allergen Protocol 2).
Combination Protocol 2
Smoke combined with OVA and HEL aerosols
This experiment aimed to measure the immune respon-
siveness after chronic OVA and smoke exposure. OVA and
Smoke or Air exposures were performed as in Combination
Protocol 1 in two groups of mice (OVA/Smoke and OVA/
Air groups; n = 8/group). The protocol was extended by
subsequently re-sensitizing these mice to HEL (HEL/alum
i. p.), and re-challenging them as described above. Mean-
while, the smoke exposures were continued in the test
group ('OVA/HEL/Smoke' group), while remaining
absent in the control group ('OVA/HEL/Air' group; Figure
1- Combination Protocol 2).
Combination Protocol 3
Smoke combined with short-term OVA aerosols
To evaluate effects of the smoke exposures on the time
course of the tolerance induction, four groups of OVA sen-
sitized mice (n = 8/group) were exposed to OVA or PBS
aerosols for 2 and 4 weeks, combined with Smoke or Air.
(Figure 1-Combination Protocols 3A and 3B respectively).
Broncho-alveolar lavage fluid (BALF): cellular analysis
Twenty-four hours after the last aerosol exposure, mice
were sacrificed with i.p. pentobarbital (60 mg/kg; Sanofi,
Libourne, France). BALF was taken by instillation of HBSS
via a tracheal cannula. Three lavages with 0.3 ml HBSS fol-
lowed by three lavages with 1 ml HBSS were performed.
The recovered BALF of the first three fractions was centri-
fuged and the supernatant was used for cytokine detec-
tion. The cell pellet was then added to the rest of the
lavage fluid, centrifuged, subjected to red blood cell lysis
and resuspended for cell counts on cytospins (May-Grün-
wald/Giemsa).
Tissue processing and preparation of lung single-cell 
suspension for flow cytometric analysis
Following BALF, the pulmonary and systemic circulation
was rinsed with saline-EDTA to remove the pulmonary
intravascular pool of cells. The right lung was thoroughly
minced and incubated in digestion medium at 37°C con-
taining DNase I (grade II from bovine pancreas; Boe-
hringer Ingelheim, Germany) and collagenase type II
(Worthington Biochemical Corp., Lakewood, NJ). After
obtaining a single-cell suspension, samples were centri-
fuged and resuspended in PBS containing 10 mM EDTA.
Finally, cells were subjected to red blood cell lysis, washed
and kept on ice until labelling. Cell counting was per-
formed with a Z2 Beckman-Coulter particle counter
(Beckman-Coulter, Ghent, Belgium). Flow cytometric
analysis of dendritic cells and T-lymphocytes was defined
as detailed previously[20]. Briefly, mouse dendritic cells
populations were identified as low autofluorescent,
CD11chigh MHCII+ cells. The maturation status of the den-
dritic cells was analysed by assessing the CD86 (B7.2)
expression. Mouse T cell subpopulations were identified
as CD3+ and CD4+ or CD8+ cells. CD69 expression was
analysed to assess the activation status of the T cells. Mon-
oclonal antibodies used to identify mouse dendritic cells
populations were biotinylated anti-CD11c and phyco-
erythrin (PE)-conjugated anti-IAb and anti-CD86. Rat
IgG2a-PE was used as isotype control. Markers used for
mouse T-cell subpopulations staining were CD3-APC,
CD4-FITC, CD8-FITC and CD69-PE (activation marker).
All other monoclonal antibodies were obtained from Bec-
ton Dickinson Pharmingen (BD, Erembodegem, Bel-
gium), except anti-CD11c (N418 hybridoma; gift from M.
Moser, Brussels Free University, Belgium). Flow cytometry
data acquisition was performed on a duallaser FACSCali-
bur™ flow cytometer running CELLQuest™ software (BD,
Mountain View, CA, USA). FlowJo software (Treestar Inc.,
Ashland, OR) was used for data analysis.Respiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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Histology
After fixation of the left lung with 4% paraformaldehyde,
slices from the left lobes were embedded in paraffin for
histological analysis. Sections of 2 µm were stained with
Congo Red, counter-stained with hematoxylin, to high-
light eosinophils.
Semi-quantitative analysis of peribronchial inflammation
The slides were coded and the peribronchial (and perivas-
cular) inflammation was graded in a blinded fashion
using a reproducible scoring system [21]. A value from 0
to 3 was adjudged to each tissue section scored. A value of
0 was given when no inflammation was detectable, a
value of 1 for occasional cuffing with inflammatory cells,
a value of 2 when most bronchi were surrounded by a thin
layer (1 to 5 cells) of inflammatory cells and a value of 3
when most bronchi were surrounded by a thick layer (>5
cells) of inflammatory cells. As 5–7 tissue sections per
mouse were scored, inflammation scores could be
expressed as a mean value per animal and could be com-
pared between groups.
Lymph node cultures
Paratracheal and parathymic intrathoracic lymph nodes
were removed. These mediastinal lung-draining lymph
nodes were harvested into Tissue Culture Medium (TCM)
containing tubes and digested enzymatically (colla-
genase/DNase) to obtain a single-cell suspension. Cells
were cultured in TCM in a flat-bottom, 96 well plate (BD)
alone or with 3 µg OVA or HEL, at a density of 8 × 105 cells
per well. After 5 days of culture, supernatants were har-
vested and used for cytokine measurements.
IgE, cytokines and chemokines (ELISA)
Total, OVA- and HEL-specific serum IgE was measured
with ELISA using coated microtiter plates and biotinylated
polyclonal rabbit anti-mouse IgE (S. Florquin, ULB, Brus-
sels, Belgium). OVA- and HEL- specific IgE are expressed
in arbitrary units (U) per ml serum. ['OVA-IgE Units'
(OVA-U) or 'HEL-IgE Units' (HEL-U)/ml]. One 'OVA-IgE
Unit' was defined as a 1/100 dilution of an internal stand-
ard serum pool obtained from OVA (10 µg)/alum (1 mg)
sensitized mice. One 'HEL-IgE Unit' was defined as a 1/
100 dilution of an internal standard serum pool obtained
from HEL (10 µg)/alum (1 mg) sensitized mice.
IL-13, TARC, IFN-γ, MCP-1, KC and eotaxin were deter-
mined on BALF fluid supernatant and IL-13, TARC, IFN-γ
were measured on the supernatant of cultured lymph
node cells using ELISA kits (R&D Systems, Abingdon,
UK).
Statistical analysis
Data were analysed with the statistical packet SPSS 15.0
(SPSS Inc.; Chicago, IL). Values are expressed as mean +/-
Standard Error of the Mean (SEM). Groups were com-
pared using the Kruskall-Wallis test for screening signifi-
cant differences between the groups. When p < 0.05,
Mann-Whitney U-test with Bonferroni's conservative cor-
rections were applied to compare the individual groups.
Results
1) Biological effects of repeated exposures to allergen or 
smoke
In a first experiment, sensitized C57BL/6 mice were chal-
lenged with OVA aerosol for 2 weeks to induce an asthma-
like Th-2 driven inflammatory response in the airways
(Figure 1 – Allergen Protocol 1A). Next, we prolonged the
exposure to OVA aerosols up to 8 weeks (Figure 1- Allergen
Protocol 1B). As previously described [3], this treatment
made the allergen-induced eosinophilic airway inflamma-
tion disappear completely (data not shown).
Next, to document the biological effect of the applied
smoke protocol for 8 weeks, C57BL/6 mice were exposed
to either Smoke or Air for 8 weeks (Figure 1- Smoke Proto-
col). Analysis showed that BALF leukocytes, macrophages,
neutrophils and lymphocytes were significantly increased
in smoke exposed mice (Figure 2A). Furthermore, MCP-1
(Monocyte Chemotactic Protein-1 or CCL2) and KC
(cytokine-induced neutrophil chemo-attractant or mouse
IL-8, CXCL chemokine) were elevated in BALF superna-
tant (Figure 2B). Histopathology showed that the bronchi
were infiltrated with mononuclear cells and neutrophils
after 8 weeks exposure to cigarette smoke (not shown).
2) The fading of allergic inflammation by prolonged OVA 
aerosol challenge is not reversed by cigarette smoke
Next, we evaluated the effects of smoke exposure on the
establishment of immune tolerance. Four groups of OVA-
sensitized C57BL/6 mice (n = 8/group) were exposed to
Smoke or Air combined with OVA or PBS aerosols for 8
weeks (Figure 1- Combination Protocol 1).
Airway inflammation
Mice exposed for 8 weeks to OVA inhalations only ('OVA/
Air') displayed no detectable airway inflammation. His-
tology (Figure 3), cytology of BALF and lung (Figure 4A–
D), and Th-1/Th-2 cytokines (Figure 4E–F) were compara-
ble between PBS/Air and OVA/Air exposed mice. In con-
trast, mice exposed to smoke alone without OVA ('PBS/
Smoke'), displayed a mild inflammatory response in the
airways due to the effects of cigarette smoke, characterized
by neutrophils, macrophages and dendritic cells in BALF
and lung tissue (Figure 3 and 4). There was an increase in
number and percentage of activated T-cells (CD4+CD69+
and CD8+CD69+ T-cells) in the lung tissue.
In mice exposed to both OVA and smoke ('OVA/Smoke'),
we did not observe a re-activation of Th-2 driven airwayRespiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
Page 6 of 14
(page number not for citation purposes)
inflammation. In particular, there was no eosinophilic
influx in BALF or in the airways as compared to the other
groups (Figure 3 and 4A–B). The numbers and percent-
ages of dendritic cells in BALF (data not shown) and lung
and activated lung T-cells were comparable with mice
exposed to cigarette smoke only (Figure 4C and 4D).
Remarkably, the increase in BALF neutrophilia was signif-
icantly less pronounced as compared to the mice that were
exposed to cigarette smoke only (PBS/Smoke vs OVA/
Smoke, p < 0.05), which indicates an attenuated inflam-
matory response to the smoke in tolerized mice (Figure
4A). Airway histology showed infiltration of mononu-
clear cells and neutrophils in both smoke -exposed
groups, while the infiltration was absent in mice exposed
to PBS/Air or OVA/Air. Again this tissue inflammatory
reaction was significantly less pronounced in the OVA/
Smoke group as compared to the PBS/Smoke group (Fig-
ure 3 and 4B).
Cytokines
IL-13 in the BALF was around (PBS/Smoke group) or
below (other groups) the detection limit (1–2 pg/ml)
(Figure 4E). TARC was elevated in response to cigarette
smoke, and this increase was less pronounced when OVA
and smoke were combined (Figure 4E). MCP-1 and KC
were elevated in both cigarette smoke exposed groups, but
this increase tended to be lower in the group with com-
bined exposures (For MCP-1: p = 0.083 PBS/Smoke vs
OVA/Smoke; for KC: p = 0.065 PBS/Smoke vs OVA/
Smoke; Figure 4F). Eotaxin in BALF was below the detec-
tion limit in all groups.
In the supernatant of cultured lymph node cells, higher
constitutive levels of the Th-2 cytokine IL-13 were meas-
ured, but no differences between the groups were found
(data not shown). IFN-γ was elevated in supernatant of
cultured lymph node cells in response to smoke (data not
shown). Again, this increase in IFN-γ was less pronounced
in the group were cigarette smoke was combined with
OVA aerosols (p < 0.05 PBS/Smoke vs OVA/Smoke).
Serum IgE
Total- and OVA-specific serum-IgE were comparably ele-
vated in both OVA-exposed groups.(OVA-IgE: 25.75 ±
8.51 U/ml in OVA/Air vs 35.40 ± 9.47 U/ml in OVA/
Smoke; p = 0.38).
3) Mainstream cigarette smoke exposure does not reverse 
the induction of functional bystander tolerance
Next, as combined OVA and mainstream cigarette smoke
exposure for 8 weeks induced neither a persistent allergic
airway inflammation nor an allergy exacerbation, we eval-
BALF cell differentiation (A) and BALF cytokines (pg/ml) MCP-1 and KC (B) after 8 week exposure to Smoke or Air in C57BL/ 6 mice (Smoke Protocol) Figure 2
BALF cell differentiation (A) and BALF cytokines (pg/ml) MCP-1 and KC (B) after 8 week exposure to Smoke 
or Air in C57BL/6 mice (Smoke Protocol). n = 6 mice/group. * p ≤ 0.05: Smoke vs Air (Mann-Whitney U test); Bars indi-
cate mean ± SEM. ND = Not Detectable (detection limit = 1–2 pg/ml).Respiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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uated at the functional level in vivo whether the tolerance
mechanisms effectively remained active. Therefore, we
implemented Allergen protocol 2, but in the presence of cig-
arette smoke (Figure 1- Combination Protocol 2). The first
group of mice was exposed to 8 weeks of OVA, then re-
immunized and re-challenged with HEL ('OVA/HEL/Air'
group); the second group was identically treated, but was
concurrently exposed to cigarette smoke ('OVA/HEL/
Smoke' group).
Histology (Congo Red) of the airways of the four groups of mice after 8 week exposure to OVA or PBS aerosols combined  with Smoke or Air in sensitized C57BL/6 mice (Combination Protocol 1) (Magnification = 400×; A = PBS/Air, B = PBS/Smoke, C  = OVA/Air, D = OVA/Smoke) Figure 3
Histology (Congo Red) of the airways of the four groups of mice after 8 week exposure to OVA or PBS aerosols combined 
with Smoke or Air in sensitized C57BL/6 mice (Combination Protocol 1) (Magnification = 400×; A = PBS/Air, B = PBS/Smoke, C 
= OVA/Air, D = OVA/Smoke).Respiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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Results obtained from combining 8 weeks OVA or PBS aerosol exposure with Smoke or Air in sensitized C57BL/6 mice (Com- bination Protocol 1) Figure 4
Results obtained from combining 8 weeks OVA or PBS aerosol exposure with Smoke or Air in sensitized 
C57BL/6 mice (Combination Protocol 1). (A.) BALF analysis of total cell counts and differentiation after prolonged expo-
sure (8 weeks) to a combination of OVA or PBS aerosols and Smoke or Air. (B) Evaluation of the peribronchial inflammation 
via a semi-quantitative method (Mean score/airway). (C) Percentage of T – lymphocytes in lung that are CD4+CD69+ (as a per-
centage within the T cell population). (D) Percentage of dendritic cells in digested lung tissue (percentage of total lung cells). (E) 
Th-2 cytokine (IL-13 and TARC) profiles in BALF (pg/ml). (F) Cytokines MCP-1 and KC in BALF (pg/ml). n = 8 mice/group; bars 
indicate mean ± SEM. * p ≤ 0.05: all groups vs PBS/Air (Mann-Whitney U test); + p ≤ 0.05: PBS/Smoke vs OVA/Smoke (Mann-
Whitney U test); # p ≤ 0.05: OVA/Smoke vs OVA/Air (Mann-Whitney U test); ND = Not Detectable (detection limit = 1–2 pg/
ml)Respiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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The inflammatory cells in BALF as well as the tissue
inflammation and serum HEL-specific IgE (not shown)
showed that there was no renewal of Th-2 driven eosi-
nophilic airway disease in the OVA/HEL/Smoke group
(Figure 5). This was also underscored by the measure-
ments of Th-1/Th-2 cytokines in BALF (IL-13, TARC and
eotaxin were below detection limit in both groups) and in
supernatant of cultured lymph node cells (not shown).
The only parameters that were different between both
groups were neutrophils in BALF and neutrophils and
mononuclear cell infiltrates around the airways (histol-
ogy) in the OVA/HEL/Smoke group, to be attributed to
the effects of the tobacco smoke.
4) Cigarette smoke exposure enhances the magnitude of 
an acute inflammatory response and slows down the time 
course of tolerance induction
Finally, we tested whether combined OVA aerosol and
mainstream cigarette smoke exposure could have an influ-
ence on the time course of the tolerance induction. In
order to investigate this, we concurrently exposed four
groups of mice to Smoke or Air and OVA or PBS aerosols
for 2 and 4 weeks (Figure 1- Combination Protocols 3A and
3B respectively).
Combined exposure for 2 weeks (Combination Protocol 3A)
resulted in an augmented acute Th-2 mediated airway
inflammation in OVA/Smoke exposed mice compared
with OVA/Air exposed mice. This was evident from BALF
analysis (Figure 6A), Th-2 cytokines (Figure 6B), histology
(not shown) and lung dendritic cells and activated CD4+
T cells (Table 1). KC and MCP-1 were elevated in BALF of
both smoke-exposed groups of mice, while eotaxin was
only detectable in both OVA-exposed groups (not
shown). CD86 expression on dendritic cells was increased
in response to OVA exposure alone, as well as in response
to combined OVA/Smoke exposure (Table 1). OVA-IgE
tended to be higher in OVA/Smoke compared to OVA/Air
exposed mice (Table 1; p = 0.074 OVA/Air vs OVA/
Smoke).
Next, we investigated the influence of combined expo-
sures on the time course of the tolerance induction by giv-
ing the mice both stimuli for 4 weeks (Combination
Protocol 3B). The eosinophilic airway inflammation had
almost completely disappeared in OVA/Air exposed mice.
In contrast, a limited though significant airway eosi-
nophilia remained present in OVA/Smoke mice (Figure
6C). IL-13 was below the detection limit in all groups.
Results obtained 8 weeks of OVA aerosols followed by re-sensitisation (i. p.) and re-challenge to HEL aerosols (Allergen Protocol  2) combined with concurrent Smoke or Air-exposures (Combination Protocol 2) Figure 5
Results obtained 8 weeks of OVA aerosols followed by re-sensitisation (i. p.) and re-challenge to HEL aerosols (Allergen Protocol 
2) combined with concurrent Smoke or Air-exposures (Combination Protocol 2). (A) BALF cell differentiation. (B) Peribronchial 
inflammation (Mean score/airway). n = 8 mice/group; bars indicate mean ± SEM. * p ≤ 0.05: OVA/HEL/Smoke vs OVA/HEL/Air 
(Mann-Whitney U test);Respiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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TARC (Figure 6D) was elevated in the OVA/Smoke
exposed group compared to the OVA/Air group. The eosi-
nophil chemo-attractant eotaxin in BALF was only detect-
able in the BALF of OVA/Smoke mice (5.20 ± 0.49 pg/ml),
while being below the detection limit (<1–2 pg/ml) in the
other groups. KC and MCP-1 were elevated in both
smoke-exposed groups (data not shown). The observa-
tions in BALF were further underscored by measurements
of IL-13 and TARC on supernatant of cultured lung-drain-
ing lymph node cells and by histology of the airways (not
shown). The number of dendritic cells in the lung was ele-
vated in both smoke- exposed groups, while activated
CD4+ T cells were elevated in the OVA/Smoke group as
compared to mice exposed to OVA alone (Table 1). The
percentage of CD86 positive lung dendritic cells was sig-
nificantly increased compared to PBS/Air mice in
response to smoke alone and OVA/Smoke, but not to
OVA alone (Table 1). Serum OVA-IgE remained elevated
in both OVA challenged groups, but cigarette smoke expo-
sure had, as for 2 weeks, no significant additive effect
(Table 1; p = 0.40, OVA/Air vs OVA/Smoke).
Figure 7 represents a time curve to summarize these find-
ings. We selected two important parameters, namely BALF
eosinophilia and TARC. This figure illustrates the effects
of combined cigarette smoke and OVA aerosol exposure
for 2, 4 and 8 weeks. Figure 7 shows that cigarette smoke
exposure initially augmented airway eosinophilia and
BALF TARC levels and later on slowed down the onset of
tolerance.
Discussion
The objective of this study was to evaluate the effects of
mainstream cigarette smoke in a mouse model of inhala-
tional tolerance. We show that a state of disease inhibition
or 'tolerance', as we refer to this state of unresponsiveness
to re-sensitization and re-challenge, can be induced in
mice suffering allergic airway inflammation, despite con-
current exposure to both mainstream cigarette smoke and
inhaled allergen. The smoke – induced inflammation
even appeared attenuated in these tolerized mice. Impor-
tantly, mainstream cigarette smoke enhanced the acute
allergic inflammation and slowed down the time course
of tolerance induction.
We combined the 8 weeks OVA aerosol exposure proto-
col, sufficient to induce tolerance in sensitized C57BL/6
mice, with cigarette smoke (Combination Protocol 1) and
found that cigarette smoke did not prevent the establish-
ment of tolerance due to prolonged OVA aerosol chal-
lenge. In general, functional tolerance in vivo can be
proven by re-immunization and challenge with the same
or with bystander allergens. This experimental approach
has been used to prove primary inhalational tolerance
[22] or oral tolerance [23] in naïve mice. We previously
also applied the same approach to this model of pro-
longed OVA aerosol challenge and we discovered that,
after the eosinophilic inflammation had disappeared, re-
immunization and short-term allergen re-challenge did
not result in the re-appearance of allergic airway disease,
and that this phenomenon had memory characteristics
[3]. Here, re-immunization and re-challenge of the mice
with the secondary antigen HEL in the presence of ciga-
rette smoke (Combination Protocol 2) additionally showed
that, also at the functional level, no Th-2 mediated
immune responses could be mounted, despite the ciga-
rette smoke. In line with these findings, one recent study
also found no evidence of increased allergic inflammatory
responses in a model of combined long-term OVA and
Table 1: Serum- IgE and Flow Cytometric data
2 weeks PBS/Air PBS/Smoke OVA/Air OVA/Smoke
OVA – IgE (U/ml) 0.97 ± 0.40 2.30 ± 0.50 14.02 ± 4.44* 20.00 ± 4.38*
Total IgE (µg/ml) 0.05 ± 0.01 0.09 ± 0.02 0.52 ± 0.37* 0.56 ± 0.25*
Lung dendritic cells (perc.) 0.94 ± 0.06 1.41 ± 0.07* 1.74 ± 0.16* 1.90 ± 0.23*
Lung CD4+CD69+ T cells (perc. of T cells) 7.00 ± 1.09 9.69 ± 0.74* 13.88 ± 1.29* 18.52 ± 2.04*#
Lung CD86+ dendritic cells (perc. of DC) 53.27 ± 2.58 59.03 ± 0.96 63.84 ± 2.84* 65.62 ± 2.18*+
4 weeks PBS/Air PBS/Smoke OVA/Air OVA/Smoke
OVA- IgE (U/ml) 2.75 ± 0.79 3.67 ± 0.70 35.23 ± 9.06* 55.22 ± 8.22*
Total IgE (µg/ml) 0.17 ± 0.05 0.16 ± 0.03 0.24 ± 0.068 0.33 ± 0.074
Lung dendritic cells (perc.) 1.07 ± 1.29 2.09 ± 0.13*+ 1.33 ± 0.52 1.53 ± 0.86*
Lung CD4+ CD69+T cells (perc. of T cells) 8.36 ± 0.90 14.29 ± 1.81* 13.57 ± 0.63* 18.16 ± 1.06*#
Lung CD86+DC (perc. of DC) 55.33 ± 3.22 73.21 ± 1.31* 63.07 ± 1.99 72.32 ± 1.17*#
n = 8 mice/group; bars indicate mean ± SEM
* p ≤ 0.05: all groups vs PBS/Air (Mann-Whitney U test);
+ p ≤ 0.05: OVA/Smoke vs. PBS/Smoke (Mann-Whitney U test);
# p ≤ 0.05: OVA/Smoke vs. OVA/Air (Mann-Whitney U test);Respiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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tobacco smoke exposure, although another method of
tobacco smoke exposure (nose-only) was used [24].
Remarkably, some parameters indicated that the inflam-
matory response to smoke was even attenuated in the
mice concurrently subjected to the 8 weeks inhalational
tolerance protocol. These findings suggest that the toler-
ance mechanisms could also dampen the airways'
response to other pro-inflammatory stimuli or airway irri-
tants. Since one of the proposed mechanisms is the induc-
tion of regulatory T cell activity, it is interesting to note
that allergen-induced regulatory T cells can inhibit both
Th-2 [25] and Th-1 responses in vivo, while they can also
dampen the activation of the innate immune system [1].
BALF cell differentiation and cytokines (pg/ml) IL-13 and TARC after respectively 2 (Fig. 6A and 6B) and 4 (Fig. 6C and 6D)  weeks of concurrent exposure to OVA/PBS and Smoke or Air in C57BL/6 mice (Combination Protocol 3A and 3B) Figure 6
BALF cell differentiation and cytokines (pg/ml) IL-13 and TARC after respectively 2 (Fig. 6A and 6B) and 4 (Fig. 6C and 6D) 
weeks of concurrent exposure to OVA/PBS and Smoke or Air in C57BL/6 mice (Combination Protocol 3A and 3B). n = 8 mice/
group; bars indicate mean ± SEM. * p ≤ 0.05: all groups vs PBS/Air (Mann-Whitney U test); + p ≤ 0.05: OVA/Smoke vs. PBS/
Smoke (Mann-Whitney U test); # p ≤ 0.05: OVA/Smoke vs. OVA/Air (Mann-Whitney U test); ND = Not Detectable (detection 
limit = 1–2 pg/ml)Respiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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However, in contrast with primary inhalational tolerance
in naïve animals, where an important role for regulatory T
cells has been documented [22,26], we previously could
not find any increases in the numbers of 'naturally occur-
ring' CD4+CD25+Foxp3+ regulatory T cells in lung tissue
upon chronic antigen inhalation [3]. Although this find-
ing did not preclude the induction of other regulatory T
cells subsets and gave no definite answer about the activity
of these cells, it is tempting to speculate that regulatory T
cell-independent mechanisms might be involved, such as
induction of anergy, depletion of the T cells, and immu-
nosuppressive activity of alveolar macrophages. In sup-
port of this hypothesis, inhibition of immune responses
by repeated allergen challenge could also be obtained in
one model in the absence of regulatory T cells, as shown
by adoptive transfer experiments in RAG1-/- mice [27].
Recent data also showed the involvement of complement
factor C5a in inhalational tolerance in naïve mice [28],
although conflicting results have been published about its
precise role during the course of an allergic inflammatory
response [28-30]. Consequently, the role of the comple-
ment in inducing and/or maintaining inhalational toler-
ance through prolonged allergen challenge in sensitized
mice has to be delineated further.
Although we had to reject our primary hypothesis that cig-
arette smoke could prevent tolerance establishment, we
here documented that cigarette smoke exposure could
influence the kinetics of the tolerance induction. Firstly, 2
weeks of concurrent exposure (Combination Protocol 3A)
augmented the acute allergic airway inflammation in
experimental asthma. This confirmed our previous obser-
vations of the aggravating effects of cigarette smoke on
acute allergic inflammation in a BALB/c model of acute
allergic airway inflammation [17]. In this model, a signif-
icant increase in OVA-IgE was also observed in response to
concurrent short-term OVA and smoke exposure, while
here only a trend was observed. These differences in
response can be attributed to the fact that the BALB/c
strain is naturally a high-IgE responder [31], in contrast to
the C57BL/6 strain used here, which is lower-IgE
responder to systemic sensitization. Secondly, combined
exposures for 4 weeks (Combination Protocol 3B) showed
that cigarette smoke significantly slowed down the onset
of tolerance. We found persistence of airway eosinophilia
and Th-2 mediators in OVA/Smoke mice but not in OVA/
Air mice. This result clearly showed that tobacco smoke
could influence the time course of the tolerance establish-
ment.
A potential underlying mechanism involved in these phe-
nomena is that mainstream tobacco smoke could exert
pro-allergic effects by enhancing the maturation status
and migration of the dendritic cells in the airways, either
directly via its effects on the sub-epithelial dendritic cells
[32,33] or indirectly via stimulating the airway epithelium
to release dendritic cell maturation stimuli such as TSLP
and GM-CSF [34]. Over-expression of these growth factors
in the airways have been shown to break inhalational tol-
erance [4,35,36]. Recently, a more mature dendritic cell
phenotype has also been found in smokers [37]. On the
other hand, inhibition of dendritic cell maturation in
response to smoke has also been described in other stud-
ies using different exposure protocols [38], or in vitro con-
ditioning of human dendritic cells with cigarette smoke
extract [39], as well as in some human studies [40].
Although we here found a significant increase in the
expression of CD86 on pulmonary dendritic cell after 4
weeks of OVA/Smoke exposure, the exact role of the den-
dritic cell maturation status and migration to the lymph
nodes in the exacerbated acute inflammation and the
delay in tolerance induction remains to be established.
It is also possible that other cigarette smoke -related fac-
tors can co-determine the immune responses in our
The evolution in the levels of TARC in BALF (pg/ml) and the  percentage of eosinophils in BALF over time after 2, 4 and 8  weeks of concurrent exposure to OVA/PBS and to Smoke or  Air in C57BL/6 mice (Combination Protocol 1, 3A and 3B) Figure 7
The evolution in the levels of TARC in BALF (pg/ml) and the 
percentage of eosinophils in BALF over time after 2, 4 and 8 
weeks of concurrent exposure to OVA/PBS and to Smoke or 
Air in C57BL/6 mice (Combination Protocol 1, 3A and 3B). # p ≤ 
0.05: OVA/Smoke vs. OVA/Air (Mann-Whitney U test);Respiratory Research 2008, 9:42 http://respiratory-research.com/content/9/1/42
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model at the various time points, either directly or indi-
rectly by influencing the dendritic cells. Lipopolysaccha-
ride (LPS) is, among other danger signals, abundantly
present in tobacco smoke. The effects of LPS on the
immune system in general, and on the dendritic cell-T cell
axis in particular, are dose dependent. As such, it was
shown that low doses of LPS favour Th-2 responses
whereas higher dosages usually suppress Th-2 responses
in both humans and mice [41-45]. Concurrent allergen
and cigarette smoke for longer time periods could thus
have totally different effects on the eosinophilic inflam-
mation than concurrent short-term exposures.
Relating to the clinic, it still remains to be established
whether prolonged immune stimulation by the continu-
ous 'therapeutic' administration of allergen in order to
either exhaust allergen specific Th-2 memory cell popula-
tions or induce (regulatory T cell mediated) tolerance is a
feasible approach [46]. Nevertheless, our data here indi-
cate that cigarette smoke could interfere with such
approaches.
Conclusion
This study shows that allergen-induced tolerance can be
established in experimental asthma despite concurrent
mainstream tobacco smoke exposure. Nevertheless,
tobacco smoke exposure enhances the acute allergic air-
way inflammation and slows down the induction of toler-
ance, resulting in a more persistent eosinophil-rich airway
inflammation.
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